A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study

The use of NSAIDs in cancer patients is not widespread due to concerns regarding cyclo-oxygenase-1 (COX-1) inhibition, and its effect on gastrointestinal mucosal lining resulting in gastrointestinal bleeding and perforation [19]. The development of selective COX-2 inhibitors has led to the possibility of their use in reducing tumour-mediated prostaglandin levels safely and could help alleviate or control cancer cachexia. The selective COX-2 inhibitor celecoxib has shown potent anti-tumour growth inhibitory and anti-tumour preventive effects in animal models [19].

The use of celecoxib has been investigated in eleven cachectic patients with head and neck and gastrointestinal cancer [20]. Patients were randomised to celecoxib 200 mg twice daily or placebo for 3 weeks. The patients on celecoxib reported good compliance and no adverse events were seen [20]. Patients receiving celecoxib showed a non-significant increase in body weight, (mean change +1.0 kg compared with placebo group mean change -1.3 kg), and a significant increase in mean change score of the Quality of life (QoL) Functional Assessment of Anorexia/Cachexia Treatment (FAACT) questionnaire compared to a decrease in the placebo group (P = 0.05). These results would appear to suggest that only targeting inflammatory suppression may have some benefits but will not produce a clinically significant increase in lean body mass.

Recently, Mantovani and colleagues conducted a phase II non-randomised prospective study investigating celecoxib at a dose of 300 mg per day for four months in twenty-four advanced cancer patients (mixed tumour sites) [21]. Results (see Table 1) showed a significant decrease in the pro-inflammatory cytokine tumour necrosis factor-alpha (TNF-α) levels and a significant increase in lean body mass (by bioelectrical impedance). Significant improvements were also seen in QoL European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30), performance status according to the Eastern Cooperative Oncology Group (ECOG ) PS scale, Glasgow prognostic score (GPS) and grip strength, along with good compliance and again no grade 3 or 4 toxicities [21].

EPA is an omega-3 polyunsaturated fatty acid found in oily fish which has been shown to have anti-tumour and anti-cachexia activity in animal cachexia models [22, 23]. A recent review examined the results for five hundred and eighty-seven patients across five studies and found that there was insufficient data to establish a therapeutic benefit of EPA compared to placebo or to define the optimal dose [24]. Internationally 2 g per day of EPA is used as the ideal study dose in cancer cachexia studies due to the following two studies [25, 26]. Weight stability has been shown with 2 g per day in eighteen unresectable pancreatic cancer patients. While all subjects experienced progressive weight loss before treatment, three quarters became either weight-stable, or gained weight after treatment (P < 0.002) [26]. Furthermore, Barber et al [25] reported a significant increase in lean body mass with 2.1 g per day in twenty progressive weight losing, unresectable pancreatic cancer patients after 3 weeks (P = 0.024), and after 7 weeks of treatment (P = 0.033) [25]. Overall it has been concluded from the above review [24] along with the additional results from a large double-blind, placebo-controlled study which looked at EPA at two different dosages, that EPA on its own has only marginal effects on cachexia and that it should be used in combination with other agents [27].

A range of clinical multimodal studies have been conducted examining the combined effects of Ibuprofen and megestrol acetate [14], COX-2 (celecoxib), Medroxyprogesterone acetate and oral food supplements [28], and home total parenteral nutrition, anti-inflammatory (indomethacin) and erythropoietin therapy on cachexia [29].

To date only one study has examined the potential benefits of COX-2 inhibitors and EPA in reducing the effects of cachexia. This study involved twenty-two advanced stage IIIb-IV NSCLC patients randomised to 2 g per day of fish oil/placebo vs. 2 g per day of fish oil/200 mg celecoxib twice daily [30].

Results indicated that the patients in both groups showed significantly less fatigue, lower C-reactive protein (CRP) levels and increased appetite when compared to their baseline values.

When comparing both groups, results showed significantly higher increases in hand-grip scores and body weights were seen in the fish oil/celecoxib group (Table 2). Lean mass and fat mass also showed a trend of increasing in this group [30]. Total dose of EPA used in this study was 1.080 g per day, a value approximately half of previous studies which used 2 g per day [25, 26].

In the present study it was clinically decided that the ingestion of EPA 2 g per day along with celecoxib would be an acceptable control group medication.

Muscle wasting is a combination and balance of the anabolic and catabolic pathways, with decreased protein synthesis combined with increased protein breakdown [31]. It is hypothesised that the increase in protein degradation may reflect the increased activity of the ubiquitin-proteasome pathway and the lysosmal system, and that the ubiquitin-proteasome pathway has the predominant role in patients experiencing weight loss [8]. Conversely the anabolic pathway involves the activation of the P13K/Akt and mTOR pathway [32], leading to phosphorylation and activation of its downstream target proteins, the eukaryotic initiation factor 4E binding protein and p70 ribosomal S6 kinase 1[8]. The decrease in protein synthesis is hypothesised to be due to changes to the phosphorylation of these initiation factors [8].

While a variety of pharmacological approaches have been examined for their ability to reduce or reverse cachexia in humans, one approach that has been largely ignored is that of PRT. This is most surprising as PRT has been shown to be a potent stimulus for enhancing muscle growth and strength and mass in a variety of groups including athletes, older adults and for other cancer groups [33]. PRT may down-regulate pro-inflammatory cytokine activity and increase the phosphorylation of intramuscular amino acid signalling molecules mTOR and p70 ribosomal S6 kinase 1 [33].

PRT has been used in patients with well-controlled rheumatoid arthritis with cachexia. This phase II study reported that when PRT was performed an average 2.5 times a week for 12 weeks, significant increases in total body skeletal muscle mass occurred with an adjusted (post-test scores adjusted for pre-test scores) total lean mass of 45.0 ± 0.3 kg in the training group and by 43.8 ± 0.3 in the control group (P= 0.005). PRT seemed to be a safe and effective intervention with no exacerbation of the activity of the disease [15].

Aerobic exercise and PRT has become popular in the cancer community in recent years. There is now extensive literature supporting PRT as the most effective method for improving muscle function and strength, and reducing the effects of sarcopenia in older adults [34].

Physical activity has showed consistent improvements in patient rated QoL scores, by patients that are experiencing both health and disease [35]. This benefit has been investigated in patients with cancer, although mainly in the breast cancer patient population [35]. A recent New Zealand study described a positive relationship between quality of life and physical activity in prostate cancer survivors on androgen-deprivation therapy [36]. The positive relationship between physical activity levels and quality of life in these prostate cancer survivors concurs with the findings of a systematic review examining body composition, functional performance, QoL and physical benefit of exercise in prostate cancer patients [17]. Results support the benefits of exercise in improving muscular endurance, aerobic endurance and overall QoL as well as reducing fatigue in prostate cancer patients. This review also recommended that the exercise performed should include a substantial PRT component and be group-based to facilitate greater psychosocial benefits [17]. A recent systematic review examined the benefit of an exercise intervention on health related QoL and exercise capacity specifically in NSCLC patients [37]. Exercise interventions included resistance training, stretching exercises, aerobic training and education regarding exercise, under supervised or unsupervised conditions. Sixteen studies involving thirteen patient groups were assessed. The studies included two randomised controlled trials and nine case series. It was concluded that improvements were seen in patients' exercise capacity when participating in exercise pre-operatively. For patients participating in exercise post-treatment, improvements in exercise capacity was seen, but results for health-related QoL were conflicting [37]. None of the above studies looked at exercise in relation to the symptom of cachexia.

In a recent review it has been shown that resistance exercise and amino acids can independently stimulate skeletal muscle synthesis and that muscle synthesis is greatly increased if amino acids, especially leucine are ingested after the resistance training exercise [38]. Studies in the older adult have confirmed that providing this nutrition after exercise increases muscle synthesis, although at a slower rate, to levels similar to younger adults [38].

Recently an open non-randomized phase II study looked at the efficacy and safety of an oral amino acid functional cluster supplementation in twenty-five cachectic cancer patients [39]. All patients had advanced cancer at mixed tumour sites. The results of this study showed a significant increase in grip strength (28.2 ± 9.5 vs. 30.4 ± 9.2, P < 0.0001), along with the trend of an increase in body weight (Kg) (53.1 ± 10.6 vs. 54.2 ± 11.1, P = 0.056). Improved levels of fatigue on the QoL multidimensional fatigue symptom inventory-short form (MFSI-SF) were seen. A decreasing score is associated with a lower level of fatigue (25 ± 8.1 vs. 22 ± 7.3, P = 0.181). Decreasing CRP (24.7 ± 18.1 vs. 17 ± 11.4, P = 0.066) and interleukin-6 (IL-6 pg/ml) levels (21.3 ± 16.4 vs. 13.7 ± 4, P = 0.157) were also seen. This study suggests that amino acid supplementation may be a beneficial option for the treatment of cancer cachexia, and the integration of an amino acid supplementation into a multi-dimensional approach based on diet, exercise, nutritional support and molecularly targeted drugs for the management of cancer cachexia should be the next step [39].

Such results provide further evidence that PRT is a potent anabolic stimulus and that the anabolic response to PRT can be augmented with pharmacological agents that target selected aspects of the catabolic pathways. The application of such a paradigm in cachectic cancer patients would therefore warrant investigation.

Intravenous and orally administered amino acids have been investigated in a number of settings in relation to protein synthesis [40]. Exercise has been shown to also have a profound effect on both muscle protein breakdown and protein synthesis [40]. After reviewing oral composition studies [39‐50], of ingestion doses between 6.7 g and 40 g, it was decided to use the amino acid composition used by the studies of Fujita et al and Dreyer et al [47, 50] as reviewed in a recent systematic review (see table 3)[38]. Therefore, the ingestion dosage for the current investigation is 20 g.

The optimal treatment for cancer cachexia is the complete removal of the tumour. Unfortunately in many advanced solid tumours this is unachievable, especially in the case of NSCLC patients. The next best options are to increase nutritional intake and to counteract the weight loss, address the anorexia and reduce inflammation, along with the metabolic alterations i.e. loss of body fat and the skeletal muscle wasting [6, 51].

Therefore, the current investigation aims to examine a novel treatment regimen that may alleviate and/or stabilise this weight loss. With the goal of increasing muscle anabolism with PRT and essential amino acids high in leucine post exercise, the overall aim is to stabilise the effect of muscle catabolism/anabolism to a net gain in muscle mass. The investigation shall employ a multi-targeted approach by utilizing data gained from the literature to target and decrease the pro-inflammatory cytokines by using a COX-2 inhibitor (celecoxib) and decrease the ubiquitin proteolytic pathway with a proteasome inhibitor EPA. This feasibility study is required before recruiting to a full study to determine if a multi-targeted therapy including PRT is acceptable to this study population along with gaining data around recruitment and retention and safety around this type of clinical study. Variance and intra-patient correlation of the secondary outcomes will then be used to power the main study.

Auckland's Cancer Cachexia evaluating Resistance Training (ACCeRT) is designed and coordinated by the Department of General Practice and Primary Health Care, University of Auckland, New Zealand. University of Auckland is responsible for overall trial management, regulatory affairs, statistical planning and analysis, trial registration (ACTRN12611000870954), and reporting as well as quality assurance. The trial will be performed at North Shore Hospice, Auckland, New Zealand.

Twenty-one patients will be recruited from local hospice day centres in Auckland and from referring clinicians based at Auckland City Hospital, Auckland.

EPA will be supplied by Health World Limited, celecoxib (Celebrex) by Pfizer Australia and New Zealand, and essential amino acids prepared by Musashi, Notting Hill, Australia.

The final protocol was approved by the Northern Y Ethics Committee, Hamilton, New Zealand (NTY/11/06/064) on the 2nd of September 2011. The clinical trial complies with the Helsinki Declaration from 2008, the Medical Association's professional code of conduct, the principles of Good clinical practice guidelines and the Federal Data Protection Act.

Written informed consent for the clinical trial ACCeRT will be obtained from each participating patient in the oral and written form before inclusion in the trial. The nature, scope and possible consequences of the trial will be explained by a physician (or Principal Investigator) in detail. The investigator will not undertake any measures for the clinical trial until valid consent has been obtained.

The primary objective of this clinical trial is to evaluate whether a multi-targeted approach encompassing resistance training element is acceptable for lung cancer patients experiencing cancer cachexia. This will be assessed by the analysis of a patient-rated Likert scored questionnaire asking 10 questions on the acceptability of the above multi targeted approach, both at week12/visit 5 and end of study visit.

NSCLC cachectic patients as determined by the following definition [52]

Q1 Has lost 5% of oedema-free body weight in the previous 3-6 months

Q2 Classification of cachexia either Mild > 5%, Moderate > 10%, Severe > 15% weight loss

Q3 If no documented weight loss, Is body mass index < 20.0 kg/m²

Q4 At least 3 out of the following 5

Secondary safety outcomes are: Serious Adverse Events (SAEs) and Adverse Events (AEs);

GPS; KS; Progression-free survival (PFS) at the end of the study; Overall compliance; Percentage of patients eligible from total number recruited; Response evaluation criteria in solid tumours (RECIST) data (if available).

Secondary measured outcomes: Lean body mass assessed by bioelectrical impedance analysis (Tanita BC-418 Segmental Body Composition Analyzer, Tanita); QoL and fatigue assessed by the following questionnaires MFSI-SF, FAACT, and WHOQOL-BREF; Serum levels of proinflammatory 'classic cachexia cytokines' (IL-1, IL-6 and TNF-α) measured by Bio-Plex Pro assay, Bio-Rad); Hand grip strength assessed by hand grip dynamometry of the dominant hand, the average of three attempts with 1 minute rest between attempts (Jamar); Leg grip strength assessed by back/leg dynamometry of the right leg, the average of three attempts with a 1 minute rest between attempts (PE018 Back Dynamometer, Access Health).

Secondary measured outcome MRI thigh skeletal muscle values as assessed 'blinded' by University of Auckland and Auckland District Health Board MRI departments. Scans will be performed at screening visit and week 20 after intervention commencement only.

All patients enrolled will be identifiable throughout the study. The investigator will maintain a personal list of patient numbers and patient names. Upon consent each patient will receive a unique identification number. After the patient's eligibility for randomisation has been assessed he/she will be randomly assigned to one of the two treatment arms in a 1: 2 ratio (EPA and celecoxib vs. EPA and celecoxib, PRT and EAA).

Both study arms receive for a period of 20 weeks; 2.09 g EPA Ethical Nutrients Hi-Strength Liquid Fish Oil oral liquid (fruit punch flavour), 5.5 mls per day and 300 mg per day of celecoxib.

Additionally, patients in the experimental group undergo two sessions a week for 20 weeks of a tailored PRT programme under the supervision of a trained exercise therapist. All PRT sessions will be carried out at North Shore Hospice. There will be a 5-10 minute warm up, followed by the exercise prescription, and a 5 minute cool-down. 20 g of essential amino acids high in leucine will be administered to the patients 1 hour after PRT.

All patients are invited to continue with compassionate use after the end of the study.

All patients must have appropriate laboratory analysis and MRI study conducted prior to study enrolment to meet eligibility criteria. Laboratory parameters will be obtained three weekly. The patient will be asked at each visit for any adverse event (SAE and AE) as well as concomitant medication. QoL questionnaire (MFSI-SF, FAACT and WHOQOL-BREF) will be handed out to all patients on screening visit, weeks 1, 3, 6, 9, 12, 16 and 20.

Patients can withdraw from study participation at any time. Patients will be taken off the study if unacceptable toxicity appears. Unacceptable toxicity is defined as serious side effect or irreversible grade 3 toxicity. After the individual ending of the study subjects will receive the best available medical and nutritional care. Patients will undergo MRI at the beginning and at the end of study. Patients will be tracked and followed up until death.

The intent-to-treat population including all patients who are randomised with study medication assignment designated according to initial randomisation, regardless of whether patients receive study medication or receive a different medication from that to which they were randomised. This will be the primary population for evaluating the acceptability, and measured outcome endpoints. The safety population consisting of all patients who received at least one dose of study medication or treatment.

This will be assessed by the summary of a patient-rated Likert scored questionnaire asking 10 questions on the acceptability of the above multi targeted approach, both at week12/visit 5 and end of study visit. Medians and ranges will be estimated.

All safety outcomes will be summarised by group. Efficacy outcomes will be analysed using general or generalised linear mixed models to obtain estimates of variances and co-variances for use in powering of a future study. Group, time and their interaction will be included as explanatory variables with a spatial covariance structure across time. Trends over time will also be examined to inform on the design of the future study (timing of measures and the most appropriate outcome measures).